



PARENTERAL DRUGS (INDIA) LTD.



Date: 11.02.2012

To
National Stock Exchange of India Limited
Exchange Plaza,
Plot No.C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai-400 051

Sub: Submission of Unaudited Financial Results for the quarter ended 31st December, 2011

Dear Sir,

Please find enclosed Unaudited Consolidated as well as Standalone Financial results of the Company for the quarter ended on 31st December, 2011.

This is for the information of the Exchange and members thereof.

You are requested to take the same on record.

Thanking You
Yours Sincerely
For Parenteral Drugs (India) Limited


Company Secretary

Encl.: a/a

PARENTERAL DRUGS (INDIA) LIMITED
REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053

UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED ON 31 ST DEC , 2011

STANDALONE					(Rs. In Lacs)
Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the current period	For the Year ended
	31-12-11 (Unaudited)	31-12-10 (Unaudited)	31-12-11 (Unaudited)	31-12-10 (Unaudited)	31-03-2011 (Audited)
Net Sales/ Income from Operations	6424.64	12754.18	17042.34	35788.85	38071.34
Other operating Income	35.24	15.97	68.88	45.65	51.85
Total Income	6459.88	12770.15	17111.22	35834.50	38123.19
Expenditure					
- Increase / Decrease In stock in trade and work in progress	-1350.23	-287.18	-1280.24	-768.45	-374.71
- Consumption of raw materials	4174.97	6343.93	9597.90	17663.77	22124.27
- Employees cost	463.33	374.98	1370.71	1097.03	1660.45
- Depreciation	300.66	197.00	820.16	591.00	1093.54
- Other Expenditure	1894.05	3687.23	5010.77	10588.69	10195.88
Total	5482.78	10315.96	15519.30	29172.04	34699.43
Profit from Operations before Other Income, Interest and Exceptional Items	977.10	2454.19	1591.92	6662.46	3423.76
Other Income	0	0	0	0	0
Profit before Interest and Exceptional Items	977.10	2454.19	1591.92	6662.46	3423.76
Interest	984.62	559.94	2718.20	1537.54	2250.87
Profit after Interest but before Exceptional Items	-7.42	1894.25	-1126.28	5124.92	1172.89
Exceptional Items	0	0	0	0	0
Profit from ordinary activities before tax	-7.42	1894.25	-1126.28	5124.92	1172.89
Tax Expense(Includes Deferred Tax)	51.75	394.52	155.25	1204.89	301.38
Net Profit from Ordinary Activities after Tax	-59.17	1499.73	-1281.53	3920.03	871.51
Extraordinary Items	0.00	0	0	0	0
Net Profit for the period after extra ordinary	-59.17	1499.73	-1281.53	3920.03	871.51
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	2586.68	2586.68	2586.68	2586.68
Reserves excluding Revaluation Reserves					29046.46
Earnings Per Share (EPS)					
a. Basic EPS	-0.23	5.80	-4.95	15.15	3.37
b. Diluted EPS	-0.23	5.80	-4.95	15.15	3.37
Public Shareholding					
- Number of Shares	7944924	7944924	7944924	7944924	7944924
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	7378799	2721600	7378799	2721600	3628800
- % of Shares of total shareholding of promoters	41.17%	15.18%	41.17%	15.18%	20.25%
- % of Shares of total nominal capital	28.53%	10.52%	28.53%	10.52%	14.03%
b) Non-encumbered					
- Number of Shares	10543108	15200307	10543108	15200307	14293107
- % of Shares of total shareholding of promoters	58.83%	84.81%	58.83%	84.81%	79.75%
- % of Shares of total nominal capital	40.76%	58.76%	40.76%	58.76%	55.26%

NOTES :

- The above results are reviewed by the audit committee at the meeting held on 11.02.2012 and thereafter taken on record by the Board of Directors at their meeting held on 11.02.2012.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The company has opted to furnish consolidated financial results in term of Clause 41(e) (i) of Listing Agreement and the same are being furnished to the Stock Exchange separately.
- Details of Investors complaints for the quarter ended 31st December, 2011
Unresolved at the beginning of the quarter - Nil, Received during the quarter - 6, Disposed off during the quarter-6
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALF OF THE BOARD

VINOD KUMAR GUPTA
MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 11th February, 2012



PARENTERAL DRUGS (INDIA) LIMITED

REGD. OFFICE : 340, LAXMI PLAZA, LAXMI INDUSTRIAL ESTATE, NEW LINK ROAD, MUMBAI - 400 053

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED ON 31 ST DECEMBER 2011

(Rs. In Lacs)

Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the previous period	For the Year ended
	31-12-2011	31-12-2010	31-12-2011	31-12-2010	31-03-2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Net Sales/ Income from Operations	9320.36	15703.67	25103.69	44246.85	48651.49
Other operating Income	44.40	33.02	147.26	79.83	80.14
Total Income	9374.76	15736.69	25251.15	44326.68	48731.63
Expenditure					
- Increase / Decrease in stock in trade and work in progress	-1331.79	-419.89	-1248.91	-1102.94	-308.06
- Consumption of raw materials	5852.99	7998.28	14317.20	22334.88	28486.80
- Employees cost	559.09	535.73	1693.24	1511.80	2175.29
- Depreciation	337.31	231.00	930.11	692.00	1256.95
- Other Expenditure	2715.27	4422.93	7107.97	12701.90	13340.13
Total	8132.87	12768.05	22799.61	36137.64	44951.11
Profit from Operations before Other Income ,Interest and Exceptional Items	1241.89	2968.64	2451.54	8189.04	3780.52
Other Income	0	0	0	0	0
Profit before Interest and Exceptional Items	1241.89	2968.64	2451.54	8189.04	3780.52
Interest	1178.01	658.84	3269.92	1798.49	2855.46
Profit after Interest but before Exceptional Items	63.88	2309.80	-818.38	6390.55	925.06
Exceptional Items	0	0	0	0	0
Profit from ordinary activities before tax	63.88	2309.80	-818.38	6390.55	925.06
Tax Expense(Includes Deferred Tax)	92.43	481.49	293.38	1469.93	424.36
Net Profit from Ordinary Activities after Tax	-28.54	1828.31	-1111.75	4920.62	500.70
Extraordinary Items	0	0	0	0	0
Net Profit for the period after extra ordinary items	-28.54	1828.31	-1111.75	4920.62	500.70
Paid up equity share capital (Face value of Rs.10 per share)	2586.68	2586.68	2586.68	2586.68	2586.68
Reserves excluding Revaluation Reserves					29263.33
Earnings Per Share (EPS)					
a. Basic EPS	-0.11	7.07	-4.30	19.02	1.94
b. Diluted EPS	-0.11	7.07	-4.30	19.02	1.94
Public Shareholding					
- Number of Shares	7944924	7944924	7944924	7944924	7944924
- Percentage of Shareholding	30.71%	30.71%	30.71%	30.71%	30.71%
Promoters and Promoters group Shareholding					
a) Pledged/Encumbered					
- Number of Shares	7378799	2721600	7378799	2721600	3628800
- % of Shares of total shareholding of promoters	41.17%	15.18%	41.17%	15.18%	20.25%
- % of Shares of total nominal capital	28.53%	10.52%	28.53%	10.52%	14.03%
b) Non-encumbered					
- Number of Shares	10543108	15200307	10543108	15200307	14293107
- % of Shares of total shareholding of promoters	58.83%	84.81%	58.83%	84.81%	79.75%
- % of Shares of total nominal capital	40.76%	58.76%	40.76%	58.76%	55.26%

NOTES :

- The above consolidated unaudited financial results are reviewed by the audit committee at the meeting held on 11.02.2012 and thereafter taken on record by the Board of Directors at their meeting held on 11.02.2012.
- The Company is engaged in the Pharmaceutical business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Accounting (AS - 17).
- The above financial results have been subjected to a limited review by the Statutory Auditors.
- Figures for the earlier periods have been re-grouped / re-arranged where ever necessary.
- The Standalone results have been filed with the Stock Exchnage (s) as additional information along with the consolidated results, as per the requirement of clause 41 of the Listing Agreement.

6. Standalone information:-

	(Rs. In Lacs)				
Particulars	3 Months ended	Corresponding 3 Months ended in the previous year	Year to date figures for the current period	Year to date figures for the previous period	For the Year ended
	31-12-11	31-12-10	31-12-11	31-12-10	31-03-2011
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total Income	6459.88	12770.15	17111.22	35834.50	38123.19
Profit Before Tax	-7.42	1894.25	-1126.28	5124.92	1172.89
Profit After Tax	-59.17	1499.73	-1281.53	3920.03	871.51

7. Details of Investors complaints for the quarter ended 31 st December, 2011

Unresolved at the beginning of the quarter - Nil, Received during the quarter - 6, Disposed off during the quarter-6
Unresolved at the end of the quarter - Nil

FOR AND ON BEHALF OF THE BOARD

VINOD KUMAR GUPTA
MANAGING DIRECTOR

Place : Indore (M. P.)
Date : 11 th February, 2012

